Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APO-EPO versus Epogen/Procrit in anemia of chronic kidney disease not on hemodialysis
2011-005058-70Phase 3Terminated
- Sponsor
- Apotex Inc.
- Start
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin alfa in Uraemic Anaemia and chronic kidney disease (CKD) (2 arms), sponsored by Apotex Inc. Primary endpoint: Hemoglobin response during correction phase. Started Jan 2013; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
Uraemic Anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2011-005058-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005058-70.